What insurance policy changes affect code N42.32?

There are 2 tracked policy changes affecting code N42.32, including updates from Excellus BlueCross BlueShield. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code N42.32?

Payers that have issued tracked updates for code N42.32 include: Excellus BlueCross BlueShield.

How do I get notified when code N42.32 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code N42.32. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code N42.32?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

N42.32 Insurance Policy Changes

ICD-10 N42.32 is officially defined as "Atypical small acinar proliferation of prostate." code N42.32 is referenced in 2 tracked payer policy changes from Excellus BlueCross BlueShield. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code N42.32 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Excellus BlueCross BlueShield · Effective Oct 15, 2026High impact
Magnetic Resonance Imaging (MRI) of the Prostate - (Effective Date - 2026-10-15) 6.01.46
MRI of the pelvis is considered medically appropriate for men with suspected prostate cancer who meet one of the listed indications, including men aged 40 to 75 with a PSA greater than 3 ng/ml or a very suspicious digital rectal exam plus a listed high-risk feature, men aged 45 to 75 with a PSA greater than 3 ng/ml or a very suspicious digital rectal exam, and men older than 75 with a PSA of 4 ng/ml or greater or a very suspicious digital rectal exam. A 06/18/26 update removed very low risk from the NCCN initial risk stratification criteria, added new criteria for suspected prostate cancer and for restaging, removed criteria for non-metastatic prostate cancer previously treated with prostatectomy, radiation therapy, ablation hormonal therapy or chemotherapy where PSA does not fall after prostatectomy, and removed the salvage local therapy criteria. Serial MRIs are considered not medically necessary when monitoring an elevated PSA for suspected prostate cancer, and MR guidance for needle placement is not medically necessary for prostate biopsy.
Excellus BlueCross BlueShield · Effective Sep 17, 2026Medium impact
Laboratory Testing for the Screening and Management of Prostate Cancer 2.02.48
Excellus BlueCross BlueShield policy 2.02.48 considers biomarker tests for prostate cancer that diagnose or determine a risk score investigational, including PROGENSA PCA3, 4Kscore, Prostate Health Index and ConfirmMDx. Gene expression analysis to guide management of prostate cancer is considered medically appropriate only under the listed criteria, and ArteraAI is considered investigational for management of prostate cancer. The current version is effective September 17, 2026, and its most recent change is an annual review with the policy intent unchanged.

Watch N42.32

Get one email when a payer policy names N42.32, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Magnetic Resonance Imaging (MRI) of the Prostate - (Effective Date - 2026-10-15) 6.01.46

Laboratory Testing for the Screening and Management of Prostate Cancer 2.02.48

What insurance policy changes affect code N42.32?

Which payers have updated policy for code N42.32?

How do I get notified when code N42.32 policy changes?

Why do payers change policies for code N42.32?